Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Solid Tumor and Angiogenesis-Targeted Therapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for EDIL3 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | EDIL3 (EGF-like repeats and discoidin I-like domains-containing protein 3) Recombinant Protein HEK293 expressed, High purity (>95%), Endotoxin controlled (<1.0 EU/μg). Sequence Verified. Suitable for binding assays and immunization. |
View EDIL3 Products |
| Gene Delivery | EDIL3 Promise-ORF / Lentiviral Particles Full-length ORF for stable cell line generation and expression validation. |
View EDIL3 Products |
| Benchmark Ab | Anti-EDIL3 Recombinant Antibody Recombinant positive control for assay validation and functional blocking benchmarks. |
View EDIL3 Products |
| Validator | EDIL3 siRNA Set For target knockdown verification in functional cell-based assays. |
View EDIL3 Products |
| Related Target A | ITGAV (Integrin Alpha V) Primary functional receptor for EDIL3 mediating cell adhesion and angiogenesis. |
View ITGAV Products |
| Related Target B | MFGE8 (Lactadherin) Structural homolog of EDIL3. Crucial for off-target and selectivity counter-screening. |
View MFGE8 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Integrin-binding domain conformation preservation | HEK293 Expressed (Native Glycosylation & disulfide bond folding) |
| Homolog off-target screening (MFGE8) | High-purity homologous panel proteins strictly verified by mass spectrometry |
| Lack of functional controls | Sequence-verified clinical benchmark antibodies included |
| False positive signal in binding assays | Validated siRNA included for target specificity verification |
Live EDIL3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of EDIL3 (also known as DEL1) is gaining traction as an innovative strategy to modulate the tumor microenvironment (TME). Acting as an extracellular matrix glycoprotein, EDIL3 regulates angiogenesis, vascular remodeling, and immune cell infiltration. The race for EDIL3 therapeutics is intensifying, with major players shifting focus from traditional monoclonal antibodies to multi-specific constructs and antibody-drug conjugates (ADCs). As first-generation therapies reach preclinical milestones, the next wave of R&D is targeting the synergy between EDIL3 inhibition and immune checkpoint blockade to overcome anti-VEGF resistance.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (mAb) | Biotech Startups, Academic Spin-offs | Triple-Negative Breast Cancer (TNBC), Hepatocellular Carcinoma (HCC) | Blocking Assay (Need high-purity EDIL3 to evaluate integrin-binding inhibition) |
| Antibody-Drug Conjugate (ADC) | Oncology-focused Biopharma | NSCLC, Prostate Cancer | Internalization Assay (Need sequence-verified cell lines via Lentivirus) |
| Bispecific / Multi-specific | Global Immunotherapy Leaders | Refractory Solid Tumors | Selectivity Assay (Need EDIL3 vs. MFGE8 homologous proteins) |